Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LEAP THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for LEAP THERAPEUTICS, INC.

LPTX

LEAP THERAPEUTICS, INC.

About LEAP THERAPEUTICS, INC.

Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted antibody therapies for cancer. Its lead candidate, sirexatamab (DKN-01), inhibits DKK1 to treat various cancers, including colorectal and gastric cancers. The company leverages biomarker-driven approaches, immune modulation, and proprietary technology to create therapies aimed at improving patient outcomes in oncology markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LEAP THERAPEUTICS, INC.

1
1
LEAP THERAPEUTICS, INC. Cypherpunk Technologies Reports $77.2 Million Net Loss and Strategic Shift Towards Digital Assets

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
LEAP THERAPEUTICS, INC. Leap Therapeutics Reports $4.8M Net Income in Strategic Shift to Digital Assets

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
LEAP THERAPEUTICS, INC. Cypherpunk Technologies Reports $3.3M Net Loss, Shifts Focus to Digital Assets

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LEAP THERAPEUTICS, INC. Leap Therapeutics Reports $16.6 Million Net Loss, Implements Workforce Reduction

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LEAP THERAPEUTICS, INC. Leap Therapeutics Reports $15.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LEAP THERAPEUTICS, INC. Leap Therapeutics Reports $67.6 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
LEAP THERAPEUTICS, INC. Leap Therapeutics Reports Financial Results for Q3 2024, Net Loss Decreases Despite Increased Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments